Geron (GERN) Stock Analysis
NASDAQHealthcareBiotechnology
What Geron does
Geron Corporation is an advanced-stage biopharmaceutical company dedicated to the creation and market introduction of treatments for myeloid blood cancers. Its primary drug candidate, imetelstat, is a telomerase inhibitor currently undergoing Phase 3 clinical evaluation. This therapy aims to suppress the unchecked proliferation of cancerous stem and progenitor cells characteristic of myeloid hematologic malignancies. Imetelstat is being developed to address low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. Established in 1990, Geron's corporate headquarters are located in Foster City, California.
Key metrics
ETFs linked to GERN
Broad-market and Healthcare sector ETFs an investor holding Geron is often also exposed to. Open an ETF page to see its actual top holdings.
PortView Portfolio Insights
PortView analyzes how GERN fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.
Analyze GERN in PortView →Similar companies
Frequently asked questions
- What is the ticker symbol for Geron?
- Geron trades under the ticker GERN on NASDAQ.
- Which exchange is GERN listed on?
- GERN is listed on NASDAQ.
- What sector does Geron operate in?
- Geron is classified in the Healthcare sector (Biotechnology industry).
- How can PortView help analyze GERN in a portfolio?
- PortView shows GERN's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.
The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.